Influence of pre-existing antiplatelet treatment on acute ischemic stroke patients receiving intravenous thrombolysis: a systematic review
10.3760/cma.j.issn.1006-7876.2015.01.016
- VernacularTitle:急性缺血性卒中患者静脉溶栓前抗血小板治疗安全性系统评价
- Author:
Jinhong GONG
;
Wenwei YUN
;
Yuan CHEN
;
Chunmei WENG
- Publication Type:Journal Article
- Keywords:
Brain ischemia;
Stroke;
Tissue plasminogen activator;
Platelet aggregation inhibitors;
Meta-analysis
- From:
Chinese Journal of Neurology
2015;48(1):65-70
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the influence of antiplatelet therapy prior to intravenous thrombolysis (IVT) on acute ischemic stroke (AIS) patients receiving IVT with recombinant tissue type plasminogen activator (rt-PA).Methods Researches about the safety of pre-existing antiplatelet treatment on AIS patients undergoing rt-PA IVT published before 31st December 2013 were retrieved based on internet databases.A meta-analysis of included clinical trials was performed by RevMan 5.2 and Stata 12.0 software.Simultaneously,funnel plot and Egger's test were used to evaluate the publication bias.Results A total of 10 papers were included.Eight researches based meta-analysis showed that pre-existing antiplatelet therapy increased the risk of symptomatic intracranial hemorrhage (SICH ; OR =1.67,95％ CI 1.44-1.93,P ＜ 0.01),6 researches based analysis suggested pre-existing antiplatelet therapy increased the risk of any intracranial hemorrhage (ICH ; OR =1.23,95％ CI 1.04-1.47,P ＜ 0.05) and 3 trials based analysis indicated the functional independence of patients receiving antiplatelet treatment was a bit worse than control group (OR =0.86,95％ CI0.80-0.93,P ＜0.01).Funnel plots and Egger' s test showed that there was no significant publication bias (P ＞ 0.05).Conclusions Antiplatelet therapy might increase the risk of post thrombolysis SICH and ICH,and their 3-month function independence is not so satisfied as those who had no antiplatelet agents before IVT.However,this review has limitations and the above results should be validated in future large prospective clinical studies.
